Private Advisor Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Private Advisor Group’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-7,562	Closed	-$25K	–	3932
2020 Q2	$25K	Buy	+7,562	New	+$25.8K	﹤0.01%	2472
2017 Q3	–	Sell	-8,759	Closed	-$99K	–	1524
2017 Q2	$99K	Sell	8,759 -464	-5%	-$9.48K	﹤0.01%	1332
2017 Q1	$227K	Sell	9,223 -75	-0.8%	-$1.88K	0.01%	1213
2016 Q4	$241K	Sell	9,298 -2,370	-20%	-$101K	0.01%	1055
2016 Q3	$547K	Buy	11,668 +909	+8%	+$37.7K	0.02%	617
2016 Q2	$483K	Sell	10,759 -1,589	-13%	-$86.6K	0.02%	642
2016 Q1	$813K	Buy	12,348 +1,786	+17%	+$93.2K	0.04%	426
2015 Q4	$657K	Buy	10,562 +1,727	+20%	+$122K	0.03%	514
2015 Q3	$592K	Buy	8,835 +416	+5%	+$34K	0.03%	513
2015 Q2	$819K	Buy	8,419 +1,079	+15%	+$103K	0.04%	435
2015 Q1	$686K	Buy	+7,340	New	+$625K	0.04%	463

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Private Advisor Group's MACK Position: Q3 2020 in Review

Private Advisor Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2020, closing a stake of 7,562 shares — an estimated $25K sold.

Private Advisor Group first reported a position in MACK in Q1 2015 and held it in 11 quarters. The position peaked at $819K in Q2 2015. 38 funds tracked by Wall St. Rank hold MACK as of Q3 2020.

Private Advisor Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Private Advisor Group sold 7,562 Merrimack Pharmaceuticals, Inc. shares in Q3 2020, an estimated $25K.
Private Advisor Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2015 and held it in 11 quarters.
Private Advisor Group's Merrimack Pharmaceuticals, Inc. position peaked at $819K in Q2 2015.
38 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.